Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynam...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters Vol. 21; no. 9; pp. 2759 - 2763
Main Authors: Jones, Lyn H., Baldock, Helen, Bunnage, Mark E., Burrows, Jane, Clarke, Nick, Coghlan, Michele, Entwistle, David, Fairman, David, Feeder, Neil, Fulton, Craig, Hilton, Laura, James, Kim, Jones, Rhys M., Kenyon, Amy S., Marshall, Stuart, Newman, Sandra D., Osborne, Rachel, Patel, Sheena, Selby, Matthew D., Stuart, Emilio F., Trevethick, Michael A., Wright, Karen N., Price, David A.
Format: Journal Article
Language:English
Published: Amsterdam Elsevier Ltd 01.05.2011
Elsevier
Subjects:
ISSN:0960-894X, 1464-3405, 1464-3405
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.
Bibliography:http://dx.doi.org/10.1016/j.bmcl.2010.10.132
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0960-894X
1464-3405
1464-3405
DOI:10.1016/j.bmcl.2010.10.132